01—Abstract
Summary
Summary of the 8-K filed August 6, 2024. Cited figures are marked; the original filing is the authoritative source.
Exelixis, Inc. (Nasdaq: EXEL) reported second quarter 2024 financial results for the quarter ended June 28, 2024, per Exhibit 99.1 press release dated August 6, 2024.
Total revenues were $637.2 milliona, up from $469.8 million in the prior-year quarter, with net product revenues of $437.6 million (versus $409.6 million) and collaboration revenues of $199.6 million (versus $60.2 million), driven mainly by milestone-related revenue and higher ex-U.S. royalties. GAAP net income was $226.1 million, or $0.77 per diluted share, compared with $81.2 million, or $0.25 per diluted share, a year earlier. Non-GAAP diluted EPS, which excludes stock-based compensation net of tax, was $0.84.
Research and development expenses were $211.1 millionb and SG&A expenses were $132.0 million. The quarter included a $150 million commercial milestone from partner Ipsen, based on $600 million in cumulative cabozantinib net sales over four consecutive quarters, with payment expected in the third quarter of 2024. The FDA accepted the cabozantinib supplemental New Drug Application for previously treated advanced neuroendocrine tumors under standard review, with a PDUFA target action date of April 3, 2025.
Management also updated 2024 guidance, now calling for total revenues of $1.975 billion to $2.075 billionc and net product revenues of $1.650 billion to $1.750 billion. On capital allocation, Exelixis completed its $450 million 2024 stock repurchase program, repurchasing 20.3 million shares, and the Board authorized up to an additional $500 million of repurchases through the end of 2025.
The company also announced a pipeline prioritization: it will discontinue XB002, plans a new phase 3 trial of zanzalintinib in neuroendocrine tumors (STELLAR-311) in the first half of 2025, and is advancing XL309 and XB010. It also settled CABOMETYX patent litigation with Cipla, with a license for generic entry in the U.S. beginning January 1, 2031, if approved.
02—Key points
Key Highlights
- Total revenues of $637.2 million, up from $469.8 million in the second quarter of 2023, with license revenues of $195.0 million.
- GAAP diluted EPS of $0.77 versus $0.25 a year earlier; non-GAAP diluted EPS of $0.84.
- Net product revenues of $437.6 million, including $433.3 million from CABOMETYX and $4.2 million from COMETRIQ; royalty revenues of $41.2 million.
- $150 million cabozantinib sales-based milestone earned from Ipsen, with payment expected in Q3 2024.
- FDA accepted the cabozantinib sNDA for advanced NET under standard review; PDUFA target action date of April 3, 2025.
- Updated 2024 guidance: total revenues of $1.975–$2.075 billion and net product revenues of $1.650–$1.750 billion.
- Completed the $450 million 2024 buyback and authorized an additional $500 million of repurchases through the end of 2025.
03—Questions
Frequently Asked Questions
What drove the increase in Exelixis' second-quarter 2024 revenue?
Total revenues rose to $637.2 million from $469.8 million. Net product revenues increased to $437.6 million from $409.6 million, primarily on higher sales volume and average net selling price. Collaboration revenues rose to $199.6 million from $60.2 million, mainly due to milestone revenue recognized in the quarter and higher ex-U.S. royalties from partners Ipsen and Takeda.
What is the status of the cabozantinib application for neuroendocrine tumors?
The FDA accepted the supplemental New Drug Application for cabozantinib in previously treated advanced pancreatic and extra-pancreatic NET under standard review, with a PDUFA target action date of April 3, 2025. The FDA also granted orphan drug designation for pancreatic NET. Updated CABINET results are to be presented at ESMO Congress 2024 in September.
How much capital is Exelixis returning to shareholders?
Exelixis completed its $450 million 2024 stock repurchase program, buying 20.3 million shares. The Board authorized up to an additional $500 million of repurchases through the end of 2025, which may be executed through open market purchases, block trades, accelerated share repurchases, exchange transactions, or combinations thereof. Since March 2023, the company has returned $1 billion under its programs.
What changes were made to the pipeline?
Exelixis will discontinue development of XB002, a tissue factor-targeting ADC, and plans to reallocate resources to new pivotal trials of zanzalintinib, advancing XL309, and its growing pipeline. A new phase 3 trial, STELLAR-311, comparing zanzalintinib with everolimus in pNET and epNET is planned for the first half of 2025. Preliminary results from the STELLAR-303 phase 3 colorectal cancer study are expected in 2025. Phase 1 dose-escalation of XB010 began.
What did management say about the outlook for the rest of 2024?
Management said Exelixis is well positioned for an impactful second half of 2024, citing continued growth of the cabozantinib franchise and regulatory and development objectives. Updated 2024 guidance projects total revenues of $1.975–$2.075 billion, net product revenues of $1.650–$1.750 billion, R&D expenses of $925–$975 million, and SG&A expenses of $450–$500 million, excluding restructuring-related expenses.
04—Continue